The Acceleration Continues: Vetty Named One of Nucleus Researchs Hot Companies to Watch in 2026
AUSTIN, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vetty, the one-stop shop…
SANY and Pony.ai Announce Mass-Production Readiness of Fourth-Generation Autonomous Heavy-Duty Truck
BEIJING, Dec. 8, 2025 /PRNewswire/ -- SANY Group announced that the fourth-generation…
Numeros Motors Ditches Surveys for ‘Voicebox’, Capturing Unfiltered Customer Insights for n-First Launch
BENGALURU, India, Dec. 8, 2025 /PRNewswire/ -- Voicebox (vbx.ai), the enterprise platform…
Riyadh Air and IBM Partner to Launch World’s First AI-Native Airline
Riyadh Air's AI‑powered operations create agility across the business and unify employee…
Servier’s Voranigo (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
Voranigo® has been awarded the Prix Galien USA, the Prix Galien Poland and…
Allison Worldwide Expands Global Leadership with New Europe CEO
Former Hotwire UK CEO and Edelman MD Jeremy Lucas to turbocharge Allison's…
Global Stars Confirmed as the Games of the Future Abu Dhabi 2025 Finalises Full Line-Up
Some of the biggest names in phygital sports and esports from around…
The 4th China International Supply Chain Expo Set for Beijing in June 2026
Sustained Worldwide Outreach Drives Greater Collaboration OpportunitiesBEIJING, Dec. 7, 2025 /PRNewswire/ -- …
Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
All three dose groups (50 mg, 100 mg and 200 mg) showed…
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
93% overall response and 76% complete response rates with median progression-free survival…
